本文選題：乳腺癌 + 型糖尿病　； 參考：《東南大學(xué)學(xué)報(醫(yī)學(xué)版)》2017年04期

【摘要】：目的:探討FOXC2在合并2型糖尿病乳腺癌患者腫瘤組織中的表達(dá)情況,并分析其臨床意義。方法:選取2013年1月至2015年12月77例合并2型糖尿病乳腺癌患者為實(shí)驗(yàn)組,另取80例非2型糖尿病乳腺癌患者作為對照組。手術(shù)切取患者腫瘤組織,對一部分標(biāo)本提取組織RNA,利用反轉(zhuǎn)錄-聚合酶鏈反應(yīng)(reverse transcription PCR,RT-PCR)技術(shù)檢測兩組患者癌組織中FOXC2 mRNA表達(dá)水平;對另一部分標(biāo)本石蠟切片行ER、PR、Her-2、FOXC2免疫組化檢測,對比免疫組化FOXC2表達(dá)結(jié)果與RT-PCR結(jié)果的一致性。比較兩組乳腺癌分子分型構(gòu)成比的差異,并做FOXC2表達(dá)與三陰乳腺癌(基底細(xì)胞樣型)的相關(guān)性分析。通過Kaplan Meier-plotter法分析FOXC2與乳腺癌患者預(yù)后的相關(guān)性。結(jié)果:RT-PCR結(jié)果顯示,實(shí)驗(yàn)組癌組織FOXC2 mRNA表達(dá)水平顯著高于對照組(P0.05)。免疫組化的結(jié)果顯示,FOXC2的表達(dá)水平與RT-PCR結(jié)果一致。實(shí)驗(yàn)組luminal A型占比為22.1%(17/77),luminal B型為18.2%(14/77),Her-2過表達(dá)型為24.7%(19/77),基底細(xì)胞樣型為35.1%(27/77);對照組luminal A型占比為37.5%(30/80),luminal B型為30.0%(24/80),Her-2過表達(dá)型為16.3%(13/80),基底細(xì)胞樣型為16.3%(13/80)。兩組患者luminal A型、luminal B型及基底細(xì)胞樣型占比差異有統(tǒng)計學(xué)意義(P0.05)。兩組患者FOXC2 mRNA表達(dá)水平與患者基底細(xì)胞樣型表型呈顯著正相關(guān)性(P0.05)。Kaplan Meier-plotter結(jié)果顯示,高表達(dá)FOXC2乳腺癌患者預(yù)后差。結(jié)論:FOXC2是2型糖尿病致惡性腫瘤的潛在關(guān)鍵因子。
[Abstract]:Objective: to investigate the expression of FOXC2 in breast cancer with type 2 diabetes mellitus and its clinical significance. Methods: from January 2013 to December 2015, 77 cases of breast cancer with type 2 diabetes were selected as experimental group and 80 cases of non-type 2 diabetic breast cancer as control group. Tissue RNAs were extracted from some specimens, and the expression of FOXC2 mRNA was detected by reverse transcription polymerase chain reaction (RT-PCR) technique, and the expression of FOXC2 mRNA was detected in the other paraffin sections. The results of immunohistochemical FOXC2 expression were consistent with those of RT-PCR. The difference of molecular type composition ratio between the two groups was compared, and the correlation between the expression of FOXC2 and the basal cell-like type of trinegative breast cancer was analyzed. The correlation between FOXC2 and prognosis of breast cancer patients was analyzed by Kaplan Meier-plotter method. Results the expression of FOXC2 mRNA in cancer tissues of the experimental group was significantly higher than that of the control group (P 0.05). Immunohistochemical results showed that the expression level of FOXC2 was consistent with that of RT-PCR. In the experimental group, the proportion of luminal A was 22.1g / 77luminal B was 18.2and the over-expression of Her-2 was 24.775 / 77, and that of basal cell was 35.127 / 77; in the control group, the proportion of luminal A was 37.5 / 80luminal B, the over-expression of Her-2 was 16.3 / 80, and the base-like type was 16.313 / 80 / 80. There were significant differences in luminal A type luminal B and basal cell-like type between the two groups (P 0.05). There was a significant positive correlation between the expression of FOXC2 mRNA and basal cell-like phenotype in the two groups. The results of P0.05. Kaplan Meier-plotter showed that the prognosis of the patients with high expression of FOXC2 was poor. Conclusion:% FOXC2 is a potential key factor in malignant tumor caused by type 2 diabetes mellitus.
【作者單位】： 海南醫(yī)學(xué)院附屬醫(yī)院內(nèi)分泌科;
【分類號】：R587.1;R737.9
，

本文編號：1819200